Savara (SVRA)

• Market cap: $442M
• 1 day: -2.29%
• 5 days: 3.64%
• 1 month: 12.28%
• 3 months: -20.00%
• 6 months: -8.57%
• Year to date: -16.61%
• 1 year: -39.91%
• 5 years: 26.73%
• 10 years: -91.83%
• Sector: Healthcare
• Industry: Biotechnology

About: Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.

Employees: 59

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

1,891% more call options, than puts

Call options by funds: $219K | Put options by funds: $11K

26% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 39

11% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 19

1% more funds holding

Funds holding: 134 [Q4 2024] → 135 (+1) [Q1 2025]

0.75% more ownership

Funds ownership: 94.88% [Q4 2024] → 95.63% (+0.75%) [Q1 2025]

9% less capital invested

Capital invested by funds: $500M [Q4 2024] → $457M (-$42.6M) [Q1 2025]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q4 2024] → 3 (-1) [Q1 2025]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $2 22% downside
• Avg. target: $4.75 86% upside
• High target: $8 213% upside

4 analyst ratings

• positive: 2 50%
• neutral: 2 50%
• negative: 0 0%

HC Wainwright & Co. Andrew Fein	22% downside $2	Neutral Downgraded	29 May 2025
Evercore ISI Group Liisa Bayko	22% downside $2	In-Line Maintained	28 May 2025
Guggenheim Vamil Divan	213% upside $8	Buy Maintained	28 May 2025
Wells Fargo Tiago Fauth	173% upside $7	Overweight Maintained	28 May 2025